WEST Search History

DATE: Tuesday, June 24, 2003

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR		
L11	L10 and method and (treat$ or improv$ or therap$)	162	L11
L10	L9 and (corneal epitheli$)	162	L10
L9	L8 and (integrity or health or differentiat$ or appear$)	162	L9
L8	L7 and (sustained release)	163	L8
L7	L6 and retinoid	176	L7
L6	L5 and (contact lens)	1584	L6
L5	L4 and (solution or drops or mist or gel or ointment)	1875	L5
L4	L3 and ophthal$ and (drug delivery)	2020	L4
L3	L2 and epithel$	5226	L3
L2	L1 and cornea$	23522	L2
L1	(retinoi$ or retino$ or (vitamin A) or (vit A))	26441103	L1

END OF SEARCH HISTORY

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:sssptaul53rxa

PASSWORD:
  * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS,
EMBASE' AT 12:53:51 ON 24 JUN 2003
FILE 'CAPLUS' ENTERED AT 12:53:51 ON 24 JUN 2003
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPATFULL' ENTERED AT 12:53:51 ON 24 JUN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'EUROPATFULL' ENTERED AT 12:53:51 ON 24 JUN 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)
FILE 'JAPIO' ENTERED AT 12:53:51 ON 24 JUN 2003
COPYRIGHT (C) 2003 Japanese Patent Office (JPO) - JAPIO
FILE 'MEDLINE' ENTERED AT 12:53:51 ON 24 JUN 2003
FILE 'BIOSIS' ENTERED AT 12:53:51 ON 24 JUN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)
FILE 'EMBASE' ENTERED AT 12:53:51 ON 24 JUN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   24.98      25.19

  => s (retino? or vitamin(w)A or Vit(w)A)
    2 FILES SEARCHED...
    3 FILES SEARCHED...
    6 FILES SEARCHED...
L2       323931 (RETINO? OR VITAMIN(W)A OR VIT(W)A)

=> s l2 and cornea?
L3         6359 L2 AND CORNEA?

=> s l3 and epitheli?
L4         2411 L3 AND EPITHELI?

=> s k4 and (drug delivery)
---------User Break---------

SEARCH ENDED BY USER

=> s l4 and (drug delivery)
L5          662 L4 AND (DRUG DELIVERY)

  => s l5 and (drop# or mist or gel or ointment or solution)
L6          640 L5 AND (DROP# OR MIST OR GEL OR OINTMENT OR SOLUTION)

  => s l6 and (contact lens)
L7           64 L6 AND (CONTACT LENS)

=> s l7 and epithel?
L8           63 L7 AND EPITHEL?

=> s l8 and integrity
L9           22 L8 AND INTEGRITY
```

```
 d l9 1-22

L9   ANSWER 1 OF 22  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:497471  CAPLUS
DN   137:52446
TI   Method for enhancing integrity of epithelium
     retinoic acid
IN   Lever, Andrea; Smerbeck, Richard V.
PA   Bausch & Lomb Incorporated, USA
SO   PCT Int. Appl., 13 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------          ----  ----          ---------------  ------
PI   WO 2002049613      A2    20020627      WO 2001-US46499  20011203
     WO 2002049613      A3    20030116
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
              PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
              UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
              CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002032487      A5    20020701      AU 2002-32487    20011203
     US 2002115720      A1    20020822      US 2001-23351    20011217
PRAI US 2000-256713P    P     20001219
     WO 2001-US46499    W     20011203

L9   ANSWER 2 OF 22  USPATFULL
AN     2003:100378  USPATFULL
TI     Method and apparatus for signal transmission and detection using a
       contact device
IN     Abreu, Marcio Marc, North Haven, CT, UNITED STATES
PI     US 2003069489      A1   20030410
AI     US 2002-189779     A1   20020708 (10)
RLI    Continuation of Ser. No. US 2001-827325, filed on 6 Apr 2001, GRANTED,
       Pat. No. US 6423001 Continuation of Ser. No. US 2000-575621, filed on 22
       May 2000, GRANTED, Pat. No. US 6213943 Continuation of Ser. No. US
       1999-274882, filed on 23 Mar 1999, GRANTED, Pat. No. US 6123668
       Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, GRANTED,
       Pat. No. US 6120460 Continuation-in-part of Ser. No. US 1996-707508,
       filed on 4 Sep 1996, GRANTED, Pat. No. US 5830139
DT     Utility
FS     APPLICATION
LN.CNT 5863
INCL   INCLM: 600/405.000
NCL    NCLM:  600/405.000
IC     [7]
       ICM: A61B003-16

L9   ANSWER 3 OF 22  USPATFULL
AN     2003:81451  USPATFULL
TI     Use of corneal hardening agents in enzymeorthokeratology
IN     Karageozian, Hamper, San Juan Capistrano, CA, United States
       Park, John Y., Santa Ana, CA, United States
       Karageozian, Vicken, San Juan Capistrano, CA, United States
       Baker, Phillip, Walnut Creek, CA, United States
```

Newburn, Anthony, Malibu, CA, United States
PA INSTA Pharmaceuticals, Inc., Irvine, CA, United States (U.S. corporation)
PI US [illegible] B1 [illegible]
AI US 2000-656849 20000907 (9)
RLI Continuation of Ser. No. WO [illegible], filed on 3 Mar [illegible]
PRAI US 1999-77339P 19990309 (60)
DT Utility
FS GRANTED
LN.CNT 2681
INCL INCLM: 424/094.400
INCLS: 424/094.200; 424/094.620; 424/429.000; 424/427.000; 424/978.040
NCL NCLM: 424/094.400
NCLS: 424/078.040; 424/094.200; 424/094.620; 424/427.000; 424/429.000
IC [7]
ICM: A61K038-44
EXF 424/422; 424/427; 424/429; 424/94.1; 424/94.2; 424/94.3; 424/94.62; 424/94.4; 424/78.04; 435/201; 435/183

L9 ANSWER 4 OF 22 USPATFULL
AN 2002:338063 USPATFULL
TI Lipoxin analogs as novel inhibitors of angiogenesis
IN Serhan, Charles N., Needham, MA, UNITED STATES
Fierro, Iolanda M., Rio de Janeiro, BRAZIL
PI US 2002193431 A1 20021219
AI US 2002-86609 A1 20020301 (10)
PRAI US 2001-272931P 20010302 (60)
DT Utility
FS APPLICATION
LN.CNT 2509
INCL INCLM: 514/475.000
NCL NCLM: 514/475.000
IC [7]
ICM: A61K031-335
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 22 USPATFULL
AN 2002:224703 USPATFULL
TI Methods and compositions for the treatment of keratoconus using protease inhibitors
IN Quay, Steven C., Edmonds, WA, United States
PA K-Quay Enterprises, LLC, Edmonds, WA, United States (U.S. corporation)
PI US 6444791 B1 20020903
AI US 2000-695774 20001024 (9)
PRAI US 1999-161879P 19991027 (60)
DT Utility
FS GRANTED
LN.CNT 2800
INCL INCLM: 530/380.000
INCLS: 530/381.000; 530/412.000; 530/350.000; 514/012.000; 514/912.000; 424/078.040; 424/094.640; 424/094.650; 424/094.660; 424/094.670; 424/450.000; 424/489.000
NCL NCLM: 530/380.000
NCLS: 424/078.040; 424/094.640; 424/094.650; 424/094.660; 424/094.670; 424/450.000; 424/489.000; 530/350.000; 530/381.000; 530/412.000
IC [7]
ICM: A61K035-14
ICS: A61K038-16; A61K009-127; C07K014-00; C07K017-00
EXF 424/78.04; 424/94.64; 424/94.65; 424/94.66; 424/94.67; 424/450; 424/489; 514/912; 514/12; 530/350; 530/380; 530/381; 530/412
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 22 USPATFULL

AN 2002:102125 USPATFULL
TI Method for inhibiting inflammatory disease
IN Tuse, Daniel, Menlo Park, CA, United States
Hiebert, Charles, Sunnyvale, CA, United States
Lademann, Keith E., Palo Alto, CA, United States
Waleh, Nahid, Palo Alto, CA, United States
PA Large Scale Biology Corp., Vacaville, CA, United States (U.S. corporation)
SRI International, Menlo Park, CA, United States (U.S. corporation)
PI US 6433012 B1 20020813
AI US 2000-656144 20000906 (9)
RLI Continuation-in-part of Ser. No. US 1999-274813, filed on 22 Mar 1999, now patented, Pat. No. US 6159407
PRAI US 1998-79313P 19980325 (60)
DT Utility
FS GRANTED
LN.CNT 1760
INCL INCLM: 514/532.000
INCLS: 514/535.000; 514/543.000; 424/450.000
NCL NCLM: 514/532.000
NCLS: 424/450.000; 514/535.000; 514/543.000
IC [7]
ICM: A61K031-12
EXF 514/532; 514/535; 514/543; 424/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 22 USPATFULL
AN 2002:191539 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2002102604 A1 20020801
AI US 2000-731872 A1 20001207 (9)
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)
DT Utility
FS APPLICATION
LN.CNT 28061
INCL INCLM: 435/007.100
INCLS: 536/023.100; 530/350.000
NCL NCLM: 435/007.100
NCLS: 536/023.100; 530/350.000
IC [7]
ICM: G01N033-53
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 22 USPATFULL
AN 2002:92863 USPATFULL
TI Noninvasive measurement of chemical substances
IN Abreu, Marcio Marc, North Haven, CT, UNITED STATES
PI US 2002049389 A1 20020425
US 6544193 B2 20030408
AI US 2001-790653 A1 20010223 (9)
RLI Continuation of Ser. No. US 2000-517124, filed on 29 Feb 2000, GRANTED, Pat. No. US 6312393 Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, GRANTED, Pat. No. US 6120460 Continuation of Ser. No. US 1996-707508, filed on 4 Sep 1996, GRANTED, Pat. No. US 5830139
DT Utility
FS APPLICATION
LN.CNT 11219

INCL INCLM: [illegible]
      INCLS: 600/318.000
NCL   NCLM: [illegible]
IC   [7]
      ICM: [illegible]
      ICS: A61B005-00

L4 ANSWER 9 OF 22 USPATFULL
AN   2002:94848 USPATFULL
TI   Method and apparatus for signal transmission and detection using a contact device
IN   Abreu, Marcio Marc, North Haven, CT, UNITED STATES
PI   US 2002049374   A1   20020425
      US 6423001   B2   20020723
AI   US 2001-827325   A1   20010406 (9)
RLI   Continuation of Ser. No. US 2000-575621, filed on 22 May 2000, GRANTED, Pat. No. US 6213943 Continuation of Ser. No. US 1999-274882, filed on 23 Mar 1999, GRANTED, Pat. No. US 6123668 Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, GRANTED, Pat. No. US 6120460 Continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, GRANTED, Pat. No. US 5830139
DT   Utility
FS   APPLICATION
LN.CNT 5891
INCL INCLM: 600/405.000
      INCLS: 600/399.000; 600/400.000; 600/404.000
NCL   NCLM: 600/405.000
      NCLS: 600/399.000; 600/400.000; 600/404.000; 600/561.000
IC   [7]
      ICM: A61B003-16

L4 ANSWER 10 OF 22 USPATFULL
AN   2002:92280 USPATFULL
TI   Novel antioxidants
IN   Avery, Mitchell Allen, Oxford, MS, UNITED STATES
      Pershadsingh, Harrihar A., Bakersfield, CA, UNITED STATES
PI   US 2002048798   A1   20020425
AI   US 2001-809518   A1   20010314 (9)
PRAI US 2000-189514P   20000315 (60)
DT   Utility
FS   APPLICATION
LN.CNT 4281
INCL INCLM: 435/183.000
      INCLS: 536/008.000; 549/039.000
NCL   NCLM: 435/183.000
      NCLS: 536/008.000; 549/039.000
IC   [7]
      ICM: C07H007-06
      ICS: C07D339-04; C12N009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 22 USPATFULL
AN   2001:196313 USPATFULL
TI   Contact device for placement in direct apposition to the conjunctive of the eye
IN   Abreu, Marcio Marc A. M., 3304 Dixwell Ave., North Haven, CT, United States 06473
PI   US 6312393   B1   20011106
AI   US 2000-517124   [illegible]
RLI   Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, now patented, Pat. No. US 6120460 Continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139

PT Utility
FS GRANTED
LN.CNT 7998
INCL INCLM: [illegible]
NCL NCLM: [illegible]
IC [7]
ICM: A61B003-10
EXF 600/399; 600/400; 600/404; 600/407; 600/558; 600/584; 604/19; 604/17

L9 ANSWER 12 OF 22 USPATFULL
AN 2001:51169 USPATFULL
TI Apparatus for signal transmission and detection using a contact device for physical measurement on the eye
IN Abreu, Marcio Marc, 3304 Dixwell Ave., North Haven, CT, United States 06473
PI US 6213943 B1 20010410
AI US 2000-575621 20000522 (9)
RLI Continuation of Ser. No. US 1999-274888, filed on 23 Mar 1999, now patented, Pat. No. US 6123668 Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, now patented, Pat. No. US 6120460 Continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139, issued on 3 Nov 1998
PT Utility
FS Granted
LN.CNT 5868
INCL INCLM: 600/405.000
INCLS: 600/399.000; 600/400.000; 600/404.000
NCL NCLM: 600/405.000
NCLS: 600/399.000; 600/400.000; 600/404.000
IC [7]
ICM: A61B003-10
EXF 600/399; 600/400; 600/404; 600/405; 600/558; 600/584; 604/19

L9 ANSWER 13 OF 22 USPATFULL
AN 2000:157456 USPATFULL
TI Methods for inhibiting angiogenesis
IN Tuse, Daniel, Menlo Park, CA, United States
Hiebert, Charles, Sunnyvale, CA, United States
Laderoute, Keith R., Palo Alto, CA, United States
Waleh, Nahid, Palo Alto, CA, United States
PA Large Scale Biology Corporation, Vacaville, CA, United States (U.S. corporation)
SRI International, Menlo Park, CA, United States (U.S. corporation)
PI US 6150407 20001121
AI US 1999-274813 19990322 (9)
PT Utility
FS Granted
LN.CNT 1548
INCL INCLM: 514/532.000
INCLS: 514/535.000; 514/543.000; 424/450.000; 600/562.000
NCL NCLM: 514/532.000
NCLS: 424/450.000; 514/535.000; 514/543.000; 600/562.000
IC [7]
ICM: A61K031-235
ICS: A61K031-24; A61K031-19
EXF 424/450; 514/532; 514/535; 514/543; 600/562
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 22 USPATFULL
AN 2000:137825 USPATFULL
TI Enzyme orthokeratology
IN Harris, Donald H., Laguna Niguel, CA, United States

May, Charles, San Diego, CA, United States
Karageozian, Hampar, San Juan Capistrano, CA, United States
PA IsTA Pharmaceutical, Inc., Irvine, CA, United States (U.S. corporation)
PI US [illegible] 20001017
AI US [illegible] 1997 [illegible]
RLI Division of Ser. No. US 1996-712967, filed on 12 Sep 1996 which is a continuation of Ser. No. US 1994-211749, filed on 18 Jul 1994, now patented, Pat. No. US 5620680 which is a continuation-in-part of Ser. No. US 1991-776211, filed on 15 Oct 1991, now patented, Pat. No. US 5270051
PRAI WO 1992 US8791 19921015
DT Utility
FS Granted
LN.CNT 1551
INCL INCLM: 424/400.000
INCLS: 424/429.000; 514/839.000
NCL NCLM: 424/400.000
NCLS: 424/429.000; 514/839.000
IC [7]
ICM: A61K009-00
EXF 424/429; 424/400; 514/839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 22 USPATFULL
AN 2000:127705 USPATFULL
TI Method and apparatus for signal transmission and detection using a contact device
IN Abreu, Marcio Marc, 3304 Dixwell Ave., North Haven, CT, United States 06473
PI US 6123668 20000926
AI US 1999-274882 19990323 (9)
RLI Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998 which is a continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139, issued on 3 Nov 1998
DT Utility
FS Granted
LN.CNT 5933
INCL INCLM: 600/405.000
INCLS: 600/399.000; 600/400.000; 600/404.000
NCL NCLM: 600/405.000
NCLS: 600/399.000; 600/400.000; 600/404.000
IC [7]
ICM: A61B003-16
EXF 600/558; 600/584; 600/405; 600/404; 600/400; 600/399; 604/19

L9 ANSWER 16 OF 22 USPATFULL
AN 2000:124240 USPATFULL
TI Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
IN Abreu, Marcio Marc, 5709 Elmer St., No. 102, Pittsburgh, PA, United States 15232
PI US 6120460 20000919
AI US 1998-184127 19981102 (9)
RLI Continuation of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139
DT Utility
FS Granted
LN.CNT 5864
INCL INCLM: 600/558.000
INCLS: 600/405.000
NCL NCLM: 600/558.000
NCLS: 600/405.000

IC [7]
ICM: A61B005-00
EXF 600/558; 600/594; 604/45; 604/47

L9 ANSWER 17 OF 22 USPATFULL
AN 1998:91593 USPATFULL
TI Enzyme orthokeratology
IN Harris, Donald H., Laguna Niguel, CA, United States
PA Advanced Corneal Systems, Inc., Irvine, CA, United States (U.S. corporation)
PI US 5788957 19980804
AI US 1996-712967 19960912 (8)
RLI Continuation of Ser. No. US 1994-211749, filed on 18 Jul 1994, now patented, Pat. No. US 5626865 which is a continuation-in-part of Ser. No. US 1991-776211, filed on 15 Oct 1991, now patented, Pat. No. US 5270051
DT Utility
FS Granted
LN.CNT 1703
INCL INCLM: 424/078.040
INCLS: 424/094.620; 424/423.000; 424/427.000; 424/428.000; 424/429.000; 514/912.000; 435/180.000; 435/185.000; 435/201.000; 623/004.000; 623/005.000
NCL NCLM: 424/078.040
NCLS: 424/094.620; 424/423.000; 424/427.000; 424/428.000; 424/429.000; 435/180.000; 435/182.000; 435/201.000; 514/912.000; 623/005.110; 623/906.000
IC [6]
ICM: A61F002-14
ICS: A61K037-54; C12N009-26; C12N011-08
EXF 424/94.62; 424/28.08; 424/423; 424/427; 424/428; 424/429; 514/912; 435/108; 435/182; 435/201; 623/4; 623/5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 22 USPATFULL
AN 97:38211 USPATFULL
TI Enzyme-orthokeratology
IN Harris, Donald H., Laguna Niguel, CA, United States
May, Charles, San Diego, CA, United States
Karageozian, Hampar, San Juan Capistrano, CA, United States
PA Advanced Corneal Systems, Inc., Irvine, CA, United States (U.S. corporation)
PI US 5626865 19970506
WO 9307840 19930429
AI US 1994-211749 19940718 (8)
WO 1992-US8791 19921015
19940718 PCT 371 date
19940718 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1991-776211, filed on 15 Oct 1991, now patented, Pat. No. US 5270051
DT Utility
FS Granted
LN.CNT 1787
INCL INCLM: 424/427.000
INCLS: 424/094.620; 424/423.000; 424/428.000; 424/429.000; 424/078.040; 514/912.000; 623/004.000; 623/005.000
NCL NCLM: 424/427.000
NCLS: 424/078.040; 424/094.620; 424/423.000; 424/428.000; 424/429.000; 514/912.000; 623/005.110
IC [6]
ICM: A61F002-14
ICS: A61F009-013; A61K038-48

EXF 424/447; 424/94.62; 424/426; 424/428; 424/429; 424/78.04; 514/912; 623/4; 623/5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 22 USPATFULL
AN 97:25004 USPATFULL
TI Method and composition for treating the skin
IN Mohammadi, Fatemeh, 1149 Parklawn Dr., Lexington, KY, United States 40517
Nosek, Dagmar, 208 Patchen Dr., Apt. 11B, Lexington, KY, United States 40517
PI US 5614489 19970325
AI US 1995-450430 19950525 (8)
DT Utility
FS Granted
LN.CNT 512
INCL INCLM: 514/002.000
INCLS: 514/200.000; 514/844.000; 514/847.000; 512/001.000
NCL NCLM: 514/002.000
NCLS: 512/001.000; 514/200.000; 514/844.000; 514/847.000
IC [6]
ICM: A61K038-00
ICS: A61K031-545
EXF 514/2; 514/200; 514/844; 514/847; 512/1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 22 USPATFULL
AN 93:76417 USPATFULL
TI Preparation of a polymeric hydrogel containing micropores and macropores for use as a cell culture substrate
IN Anderson, David M., 337 Squire Hall Suny, Buffalo, NY, United States 14114
PI US 5244799 19930914
AI US 1991-809259 19911217 (7)
RLI Continuation of Ser. No. US 1990-574506, filed on 23 Aug 1990, now abandoned which is a continuation of Ser. No. US 1989-323616, filed on 14 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-292615, filed on 30 Dec 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-52713, filed on 20 May 1987, now abandoned
DT Utility
FS Granted
LN.CNT 595
INCL INCLM: 435/240.230
INCLS: 424/487.000; 435/174.000; 435/180.000; 523/106.000; 525/937.000; 526/328.000; 528/310.000
NCL NCLM: 435/397.000
NCLS: 424/487.000; 435/174.000; 435/180.000; 523/106.000; 525/937.000; 526/328.000; 528/310.000
IC [5]
ICM: C12N005-00
ICS: C12N011-08; C08F020-10; C08G069-08
EXF 435/174; 435/177; 435/180; 435/182; 435/240.23; 424/484; 424/487; 523/105; 523/106; 523/113; 525/937; 521/50; 521/64; 521/65; 526/328; 528/310; 204/194; 204/403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 21 OF 22 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1154941 EUROPATFULL ED 20011213 EW 200149 FS OS

```
TIEN    Formulations for use in enzyme-orthokeratology.
TIDE    Zusammensetzung zur Verwendung in der Enzymkeratologie.
TIFR    Formulations pour usage dans l'orthokeratologie enzymatique.
IN      Harris, Donald H., 1303 Avocado, Suite 150, Newport Beach, CA 92660, US;
        May, Charles, 3311 Fourth Avenue, San Diego, CA 92103, US;
        Karageozian, Hampar, 31021 Marbella Vista, San Juan Capistrano, CA
        92675, US
PA      Ista Pharmaceuticals, Inc., 1414 Mairlands Drive, La Jolla, CA 92307, US
SO      Wila-EPS-2001-H48-T2b
DS      R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
        R NL; R SE
PIT     EPA2 EUROPAEISCHE PATENTANMELDUNG
PI      EP 1154941              A2 20011205
OD                                 20011205
AI      EP 2001 203085             19921015
PRAI    US 1991 776211             19911015
RLI     EP 608341       DIV
IC      ICM  A61F009-00
        ICS  A61F002-14

L9      ANSWER 22 OF 22  EUROPATFULL  COPYRIGHT  2003 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN      608341  EUROPATFULL  ED 20020404  EW 200213  FS PS
TIEN    ENZYME-ORTHOKERATOLOGY.
TIDE    ENZYMORTHOKERATOLOGIE.
TIFR    ORTHOKERATOLOGIE ENZYMATIQUE.
IN      HARRIS, Donald, H., 200 Newport Center Drive, Suite 110, Newport Beach,
        CA 92660, US;
        MAY, Charles, 3311 Fourth Avenue, San Diego, CA 92103, US;
        KARAGEOZIAN, Hampar, 31021 Marbella Vista, San Juan Capistrano, CA
        92675, US
PA      Ista Pharmaceuticals, Inc., 1414 Mairlands Drive, La Jolla, CA 92307, US
SO      Wila-EPS-2002-H13-T2
DS      R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
        R NL; R SE
PIT     EPB1 EUROPAEISCHE PATENTSCHRIFT   (Internationale Anmeldung)
PI      EP 608341               B1 20020327
OD                                 19940803
AI      EP 1992-922291             19921015
PRAI    US 1991-776211             19911015
RLI     WO 92-US8791          921015 INTAKZ
        WO 9307840            930429 INTPNR
REP     DE 2308144  A              DE 2426757  A
        DE 881753   C              US 1929228  A
        US 3416530  A              US 3485244  A
        US 3760807  A              US 4540417  A
IC      ICM  A61F009-00


=> FIL STNGUIDE
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                  138.67      138.88

FILE 'STNGUIDE' ENTERED AT 13:22:53 ON 24 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
```

```
LAST RELOADED: Jun 20, 2003 (20030620/UP).

=> d his

     FILE 'HOME' ENTERED AT 12:36:44 ON 24 JUN 2003

     FILE 'CAPLUS, USPATFULL, EUROPATFULL, CAPIC, MEDLINE, BIOSIS, EMBASE'
     ENTERED AT 12:37:21 ON 24 JUN 2003
L1          1437 S CARRAGEENAN# AND ANTIMICROBIAL?
L2        323931 S (RETINO? OR VITAMIN(W)A OR VIT(W)A)
L3          6358 S L2 AND CORNEA?
L4          2411 S L3 AND EPITHELI?
L5           662 S L4 AND (DRUG DELIVERY)
L6           640 S L5 AND (DROP# OR MIST OR GEL OR OINTMENT OR SOLUTION)
L7            69 S L6 AND (CONTACT LENS)
L8            69 S L7 AND EPITHEL?
L9            22 S L8 AND INTEGRITY

     FILE 'STNGUIDE' ENTERED AT 13:22:58 ON 24 JUN 2003

=> s l8 and (corneal epithel?)
             0 RETINO?
             0 VITAMIN
           222 A
             0 VITAMIN(W) A
             0 VIT
           222 A
             0 VIT(W) A
             0 CORNEA?
             0 EPITHELI?
            32 DRUG
             6 DELIVERY
             2 DRUG DELIVERY
               (DRUG(W)DELIVERY)
             0 DROP#
             0 MIST
             0 GEL
             0 OINTMENT
             1 SOLUTION
            10 CONTACT
             0 LENS
             0 CONTACT LENS
               (CONTACT(W)LENS)
             0 EPITHEL?
             0 CORNEAL
             0 EPITHEL?
             0 CORNEAL EPITHEL?
               (CORNEAL(W)EPITHEL?)
L10          0 L8 AND (CORNEAL EPITHEL?)

=> s l8 and differentiation
             0 RETINO?
             0 VITAMIN
           222 A
             0 VITAMIN(W) A
             0 VIT
           222 A
             0 VIT(W) A
             0 CORNEA?
             0 EPITHELI?
            32 DRUG
             6 DELIVERY
```

```
              2 DRUG DELIVERY
                (DRUG(W)DELIVERY
              0 DROP#
              0 MIST
              0 GEL
              0 OINTMENT
              1 SOLUTION
             10 CONTACT
              0 LENS
              0 CONTACT LENS
                (CONTACT(W)LENS)
              0 EPITHEL?
              0 DIFFERENTIATION
L11           0 L8 AND DIFFERENTIATION

=> file caplus uspatful japio europatful medline biosis embase
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.90     139.78

FILE 'CAPLUS' ENTERED AT 13:31:44 ON 24 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 13:31:44 ON 24 JUN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 13:31:44 ON 24 JUN 2003
COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'EUROPATFULL' ENTERED AT 13:31:44 ON 24 JUN 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 13:31:44 ON 24 JUN 2003

FILE 'BIOSIS' ENTERED AT 13:31:44 ON 24 JUN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 13:31:44 ON 24 JUN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

=> d his

     (FILE 'HOME' ENTERED AT 12:36:44 ON 24 JUN 2003)

     FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
     ENTERED AT 12:37:21 ON 24 JUN 2003
L1          1437 S CARRAGEENAN# AND ANTIMICROBIAL?
L2        323931 S (RETINO? OR VITAMIN(W)A OR VIT(W)A)
L3          6359 S L2 AND CORNEA?
L4          2411 S L3 AND EPITHELI?
L5           662 S L4 AND (DRUG DELIVERY)
L6           640 S L5 AND (DROP# OR MIST OR GEL OR OINTMENT OR SOLUTION)
L7            69 S L6 AND (CONTACT LENS)
L8            69 S L7 AND EPITHEL?
L9            22 S L8 AND INTEGRITY

     FILE 'STNGUIDE' ENTERED AT 13:22:53 ON 24 JUN 2003
L10            0 S L8 AND (CORNEAL EPITHEL?)
L11            0 S L8 AND DIFFERENTIATION
```

FILE 'CAPLUS, USPATFULL, CAPIO, EUROPATFULL, MEDLINE, BIOSIS, EMBASE' ENTERED AT 13:31:44 ON 24 JUN 2003

=> s l8 and (corneal epithel?)
L12 18 L8 AND (CORNEAL EPITHEL?)

=> d l12 1-18 ibib abs

L12 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:487371 CAPLUS
DOCUMENT NUMBER: 137:52396
TITLE: Method for enhancing integrity of **epithelium** **retinoic** acid
INVENTOR(S): Lever, Andrea; Smerbeck, Richard V.
PATENT ASSIGNEE(S): Bausch & Lomb Incorporated, USA
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049613	A2	20020627	WO 2001-US46499	20011203
WO 2002049613	A3	20030116		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002032487	A5	20020701	AU 2002-32487		20011203
US 2002115720	A1	20020822	US 2001-23351		20011217
PRIORITY APPLN. INFO.:			US 2000-256713P	P	20001219
			WO 2001-US46499	W	20011203

AB A method for improving the integrity of the **corneal** **epithelium** by introducing into the eye an effective amt. of a ophthalmically compatible **retinoid** sufficient to enhance the integrity of the **corneal epithelium**. For example, an ophthalmic **ointment** was formulated for treating superior **epithelial** arcuate lesions (SEALs, and/or **corneal** infiltrates contg. **retinoic** acid 0.05 mg/g, mineral oil 100 mg/g, and white petrolatum 899.9 mg/g.

L12 ANSWER 2 OF 18 USPATFULL
ACCESSION NUMBER: 2003:100378 USPATFULL
TITLE: Method and apparatus for signal transmission and detection using a contact device
INVENTOR(S): Abreu, Marcio Marc, North Haven, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069489	A1	20030410
APPLICATION INFO.:	US 2002-189779	A1	20020708 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-827325, filed on 6 Apr 2001, GRANTED, Pat. No. US 6423001 Continuation of Ser. No. US 2000-575621, filed on 22 May 2000, GRANTED, Pat. No. US 6213943 Continuation of Ser. No. US 1999-274882,

filed on 23 Mar 1999, GRANTED, Pat. No. US 6123668
Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, GRANTED, Pat. No. US 6120460 Continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, GRANTED, Pat. No. US 5895356

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JACOBSON HOLMAN PLLC, 400 SEVENTH STREET N.W., SUITE 600, WASHINGTON, DC, 20004
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Page(s)
LINE COUNT: 5863

AB Utilization of a contact device placed on the front part of the eye in order to detect physical and chemical parameters of the body as well as the non invasive delivery of compounds according to these physical and chemical parameters, with signals preferably being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the front part of the eye and in the tear film. A transensor mounted in the contact device laying on the **cornea** or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis.

L12 ANSWER 3 OF 18 USPATFULL
ACCESSION NUMBER: 2003:81451 USPATFULL
TITLE: Use of **corneal** hardening agents in enzymeorthokeratology
INVENTOR(S): Karageozian, Hamper, San Juan Capistrano, CA, United States
Park, John Y., Santa Ana, CA, United States
Karageozian, Vicken, San Juan Capistrano, CA, United States
Baker, Phillip, Walnut Creek, CA, United States
Nesburn, Anthony, Malibu, CA, United States
PATENT ASSIGNEE(S): ISTA Pharmaceuticals, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6537545	B1	20030325
APPLICATION INFO.:	US 2000-656849		20000907 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-US5135, filed on 9 Mar 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-77339P	19980309 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Lankford, Jr., Leon B.
ASSISTANT EXAMINER: Davis, Ruth A.
LEGAL REPRESENTATIVE: Knobbe Martens Olson & Bear LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2681

AB An Enzyme Orthokeratology method is provided for correcting refractive errors in the eye of a subject mammal. Accelerating reshaping of the **cornea** is accomplished by administering a **corneal**

hardening amount of a **corneal** hardening agent to the eye of the subject. Reformation is accomplished under the influence of a rigid **contact lens** or a series of lenses having a concave curvature that will correct a refractive error. The **cornea** rapidly reshapes its convex curvature to the concave curvature of the **contact lens**, rendering the eye emmetropic. The **cornea** is permitted to "harden" to retain the new emmetropic shape. After "hardening" has occurred, the lens rendering the eye emmetropic is removed.

L12 ANSWER 4 OF 18 USPATFULL

ACCESSION NUMBER:	2002:224703 USPATFULL		
TITLE:	Methods and compositions for the treatment of keratoconus using protease inhibitors		
INVENTOR(S):	Quay, Steven C., Edmonds, WA, United States		
PATENT ASSIGNEE(S):	K-Quay Enterprises, LLC, Edmonds, WA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444791	B1	20020903
APPLICATION INFO.:	US 2000-695774		20001024 (9)
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-161879P	19991027 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Carlson, Karen Cochrane		
ASSISTANT EXAMINER:	Kam, Chih-Min		
LEGAL REPRESENTATIVE:	Woodcock Washburn LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	2800		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for treating **corneal** diseases mediated by elevated protease activity include ocular administration of protease inhibitors. One or more protease inhibitors selected from an aspartic, serine, cysteine, or metallo-protease inhibitor are administered to an ocular fluid, surface, or tissue, preferably by topical administration, to inhibit proteolytic activity associated with a **corneal** disease or condition, for example keratoconus. Antiproteolytic formulations of the invention may include carriers that prolong the retention and/or enhance delivery of the protease inhibitor. These formulations can also include other therapeutic agents such as antiinflammatory or antibiotic drugs. In preferred aspects of the invention, antiproteolytic formulations are administered during periods of closed eye tear production. Also provided within the invention are implant devices for **corneal** delivery of a protease inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 18 USPATFULL

ACCESSION NUMBER:	2002:126055 USPATFULL		
TITLE:	Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide		
INVENTOR(S):	Karagoezian, Hampar L., San Juan Capistrano, CA, UNITED STATES		
	NUMBER	KIND	DATE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020064505	A1	20020530
APPLICATION INFO.:	US 2001-811638	A1	20010318 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-412174, filed on 4 Oct 1999, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STETINA BRUNDA GARRED & BRUCKER, 75 ENTERPRISE, SUITE 250, ALISO VIEJO, CA, 92656		
NUMBER OF CLAIMS:	42		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1186		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An anti-microbial liquid ophthalmic composition for direct application onto an eye of a living being. The composition includes from about 0.02 wt. % to about 0.2% wt. % chlorite compound and from about 0.005 wt. % to about 0.01 wt. % peroxy compound, at a pH between about 7.0 and 7.8. Preferably, the chlorite compound is a metal chlorite where the metal is chosen from the group consisting of sodium, potassium, calcium, and magnesium, while the peroxy compound is hydrogen peroxide. Also included are methods for treating an eye infection through application of the composition to the eye, and for cleansing a **contact lens** in place on an eye through application of the composition to the lens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 18 USPATFULL

	NUMBER	KIND	DATE
ACCESSION NUMBER:	2002:92863 USPATFULL		
TITLE:	Noninvasive measurement of chemical substances		
INVENTOR(S):	Abreu, Marcio Marc, North Haven, CT, UNITED STATES		
PATENT INFORMATION:	US 2002049389	A1	20020425
	US 6544193	B2	20030408
APPLICATION INFO.:	US 2001-790653	A1	20010223 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-517124, filed on 29 Feb 2000, GRANTED, Pat. No. US 6312393 Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, GRANTED, Pat. No. US 6120460 Continuation of Ser. No. US 1996-707508, filed on 4 Sep 1996, GRANTED, Pat. No. US 5830139		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	JACOBSON, PRICE, HOLMAN & STERN, PROFESSIONAL LIMITED LIABILITY COMPANY, THE JENIFER BUILDING, 400 SEVENTH STREET, N. W., WASHINGTON, DC, 20004		
NUMBER OF CLAIMS:	58		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	84 Drawing Page(s)		
LINE COUNT:	11219		

AB Utilization of a contact device placed on the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the conjunctiva and in the tear film. A transensor mounted in the contact device laying on the **cornea** or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye

including non-invasive blood analysis. The system utilizes eye lid motion and/or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by wires or radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like.

L12 ANSWER 7 OF 18 USPATFULL

ACCESSION NUMBER:	2002:92848 USPATFULL		
TITLE:	Method and apparatus for signal transmission and detection using a contact device		
INVENTOR(S):	Abreu, Marcio Marc, North Haven, CT, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002049374	A1	20020425
	US 6423001	B2	20020723
APPLICATION INFO.:	US 2001-827325	A1	20010406 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-575621, filed on 22 May 2000, GRANTED, Pat. No. US 6213943 Continuation of Ser. No. US 1999-274882, filed on 23 Mar 1999, GRANTED, Pat. No. US 6123668 Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, GRANTED, Pat. No. US 6120460 Continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, GRANTED, Pat. No. US 5830139		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	JACOBSON, PRICE, HOLMAN & STERN, PROFESSIONAL LIMITED LIABILTY COMPANY, THE JENIFER BUILDING, 400 SEVENTH STREET, N. W., WASHINGTON, DC, 20004		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	35 Drawing Page(s)		
LINE COUNT:	5891		

AB Utilization of a contact device placed on the front part of the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals preferably being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the front part of the eye and in the tear film. A transensor mounted in the contact device laying on the **cornea** or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system preferably utilizes eye lid motion and/or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by cable, but is preferably actively or passively radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like. Other advantages are somnolence awareness, activation of devices by disabled

individuals, a new **drug delivery** system and new therapy for ocular and neurologic disorders, and treatment of cancer in the eye or other parts of the body, and an evaluation system for the overall health status of an individual. The device quantifies non invasively the amount of the different chemical components in the blood using a contact device with suitable electrodes and membranes laying on the surface of the eye and in direct contact with the tear film or surface of the eye, with the data being preferably transmitted utilizing radio waves, but alternatively sound waves, light waves, wire, or telephone lines can be used for transmission.

L12 ANSWER 8 OF 18 USPATFULL

ACCESSION NUMBER:	2001:202646 USPATFULL		
TITLE:	Ophthalmic uses of PPARgamma agonists and PPARgamma antagonists		
INVENTOR(S):	Pershadsingh, Harrihar A., Bakersfield, CA, United States Levy, Daniel E., San Carlos, CA, United States		
PATENT ASSIGNEE(S):	Photogenesis, Inc., Los Angeles, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316465	B1	20011113
APPLICATION INFO.:	US 1999-342381		19990628 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1998-90937P		19980627 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Dees, Jose' G.		
ASSISTANT EXAMINER:	Williamson, Michael A.		
LEGAL REPRESENTATIVE:	Brinks, Hofer, Gilson & Lione		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1661		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating diseases of ocular tissues expressing the nuclear receptor PPAR.gamma., by inhibiting the inflammatory response, the neovascularization and angiogenesis, and programmed cell death (apoptosis) in these target tissues, comprising administering to a human or animal in need of treatment an effective amount of a compound that modifies the activity of PPAR.gamma., or pharmaceutically acceptable salts and solvates thereof.

Novel compounds and methods for their synthesis are provided, including a compound having the general structure: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 18 USPATFULL

ACCESSION NUMBER:	2001:196313 USPATFULL		
TITLE:	Contact device for placement in direct apposition to the conjunctive of the eye		
INVENTOR(S):	Abreu, Marcio Marc A. M., 3304 Dixwell Ave., North Haven, CT, United States 06473		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6312393	B1	20011106

APPLICATION INFO.: US [illegible] 20000229 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-184127, filed on 2 Nov 1998, now patented, Pat. No. US 6120460
Continuation-in-part of Ser. No. US 1999-[illegible], filed on 4 Sep [illegible], now patented, Pat. No. US [illegible]
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Hindenburg, Max
LEGAL REPRESENTATIVE: Jacobson Holman, PLLC
NUMBER OF CLAIMS: 62
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 158 Drawing Figure(s); 57 Drawing Page(s)
LINE COUNT: 7988

AB Utilization of a contact device placed on the front part of the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals preferably being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the front part of the eye (conjunctiva) and in the tear film. A transensor mounted in the contact device laying on the **cornea** or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system preferably utilizes eye lid motion and/or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by cable, but is preferably actively or passively radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like. Other advantages are somnolence awareness, activation of devices by disabled individuals, a **drug delivery** system and therapy for ocular and neurologic disorders, and treatment of cancer in the eye or other parts of the body, and an evaluation system for the overall health status of an individual. The device quantifies non-invasively the amount of the different chemical components in the blood using a contact device with suitable electrodes and membranes laying on the surface of the eye and in direct contact with the tear film or surface of the eye (conjunctiva), with the data being preferable transmitted utilizing radio waves, but alternatively sound waves, light wavews, wire, or telephone lines can be used for transmission.

L12 ANSWER 10 OF 18 USPATFULL
ACCESSION NUMBER: 2001:51168 USPATFULL
TITLE: Apparatus for signal transmission and detection using a contact device for physical measurement on the eye
INVENTOR(S): Abreu, Marcio Marc, 3304 Dixwell Ave., North Haven, CT, United States 06473

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6213943	B1	20010410
APPLICATION INFO.:	US 2000-575621		20000522 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-274882, filed on 23 Mar 1999, now patented, Pat. No. US 6123668
Continuation of Ser. No. US 1998-184127, filed on 2 Nov

1998, now patented, Pat. No. US 6120460
Continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139, issued on 3 Nov 1998

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hindenburg, Max
LEGAL REPRESENTATIVE: Jacobson, Price, Holman & Stern, PLLC
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 104 Drawing Figure(s); 35 Drawing Page(s)
LINE COUNT: 5868

AB Utilization of a contact device placed on the front part of the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals preferably being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the front part of the eye and in the tear film. A transensor mounted in the contact device laying on the **cornea** or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system preferably utilizes eye lid motion and/or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by cable, but is preferably actively or passively radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like. Other advantages are somnolence awareness, activation of devices by disabled individuals, a new **drug delivery** system and new therapy for ocular and neurologic disorders, and treatment of cancer in the eye or other parts of the body, and an evaluation system for the overall health status of an individual. The device quantifies non-invasively the amount of the different chemical components in the blood using a contact device with suitable electrodes and membranes laying on the surface of the eye and in direct contact with the tear film or surface of the eye, with the data being preferably transmitted utilizing radio waves, but alternatively sound waves, light waves, wire, or telephone lines can be used for transmission.

L12 ANSWER 11 OF 18 USPATFULL
ACCESSION NUMBER: 2000:137825 USPATFULL
TITLE: Enzyme-orthokeratology
INVENTOR(S): Harris, Donald H., Laguna Niguel, CA, United States
May, Charles, San Diego, CA, United States
Karageozian, Hampar, San Juan Capistrano, CA, United States
PATENT ASSIGNEE(S): ISTA Pharmaceutical, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6132735		20001017
APPLICATION INFO.:	US 1997-932974		19970918 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-712967, filed on 13 Sep 1996 which is a continuation of Ser. No. US

1994-211746, filed on 18 Jul 1994, now patented, Pat. No. US 5626865 which is a continuation-in-part of Ser. No. US 1991-779211, filed on 15 Oct 1991, now patented, Pat. No. US 5270051

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1992-US8794	19921015

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Faulkner, D.
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear, LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1531
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and apparatus for correcting refractive errors of the eye are disclosed. Accelerated reshaping of the **corneal** tissue is accomplished by administering one or more enzymes and/or other agents to the eye which temporarily soften the **cornea**. The **cornea** is thereafter fitted with a rigid **contact lens** or a series of lenses which have a concave curvature that will correct a refractive error. The softened **cornea** then rapidly reshapes its convex curvature to the concave curvature of the **contact lens** or series of lenses, thereby rendering the eye emmetropic. The enzymes and/or other agents then dissipate from the **cornea**, and the **cornea** "hardens" to retain the new emmetropic shape. After "hardening" has occurred, the lens rendering the eye emmetropic is removed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 12 OF 18 USPATFULL
ACCESSION NUMBER: 2000:127705 USPATFULL
TITLE: Method and apparatus for signal transmission and detection using a contact device
INVENTOR(S): Abreu, Marcio Marc, 3304 Dixwell Ave., North Haven, CT, United States 06473

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6123668		20000926
APPLICATION INFO.:	US 1999-274882		19990323 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-184187, filed on 2 Nov 1998 which is a continuation-in-part of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139, issued on 3 Nov 1998
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hindenburg, Max
LEGAL REPRESENTATIVE: Jacobson, Price, Holman & Stern, PLLC
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 104 Drawing Figure(s); 35 Drawing Page(s)
LINE COUNT: 5933

AB Utilization of a contact device placed on the front part of the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals preferably being transmitted continuously as electromagnetic waves, radio waves, infrared and the

like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the front part of the eye and in the tear film. A transensor mounted in the contact device laying on the **cornea** or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system preferably utilizes eye lid motion and/or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by cable, but is preferably actively or passively radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like. Other advantages are somnolence awareness, activation of devices by disabled individuals, a new **drug delivery** system and new therapy for ocular and neurologic disorders, and treatment of cancer in the eye or other parts of the body, and an evaluation system for the overall health status of an individual. The device quantifies non-invasively the amount of the different chemical components in the blood using a contact device with suitable electrodes and membranes laying on the surface of the eye and in direct contact with the tear film or surface of the eye, with the data being preferably transmitted utilizing radio waves, but alternatively sound waves, light waves, wire, or telephone lines can be used for transmission.

L12 ANSWER 13 OF 18 USPATFULL

ACCESSION NUMBER:	2000:124240 USPATFULL		
TITLE:	Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions		
INVENTOR(S):	Abreu, Marcio Marc, 5709 Elmer St., No. 102, Pittsburgh, PA, United States 15232		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6120460		20000919
APPLICATION INFO.:	US 1998-184127		19981102 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-707508, filed on 4 Sep 1996, now patented, Pat. No. US 5830139		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hindenburg, Max		
LEGAL REPRESENTATIVE:	Jacobson, Price, Holman & Stern, PLLC		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	102 Drawing Figure(s); 35 Drawing Page(s)		
LINE COUNT:	5864		

AB Utilization of a contact device placed on the front part of the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals preferably being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the front part of the eye and in the tear film. A transensor mounted in the contact device laying on the **cornea** or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system preferably utilizes eye lid motion and/or closure of the eye lid to

activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by cable, but is preferably actively or passively radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like. Other advantages are somnolence awareness, activation of devices by disabled individuals, a new **drug delivery** system and new therapy for ocular and neurologic disorders, and treatment of cancer in the eye or other parts of the body, and an evaluation system for the overall health status of an individual. The device quantifies non-invasively the amount of the different chemical components in the blood using a contact device with suitable electrodes and membranes laying on the surface of the eye and in direct contact with the tear film or surface of the eye, with the data being preferably transmitted utilizing radio waves, but alternatively sound waves, light waves, wire, or telephone lines can be used for transmission.

L17 ANSWER 14 OF 18 USPATFULL

ACCESSION NUMBER:	1998:91593 USPATFULL		
TITLE:	Enzyme-orthokeratology		
INVENTOR(S):	Harris, Donald H., Laguna Niguel, CA, United States		
PATENT ASSIGNEE(S):	Advanced Corneal Systems, Inc., Irvine, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5788957		19980804
APPLICATION INFO.:	US 1996-712967		19960912 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-211749, filed on 18 Jul 1994, now patented, Pat. No. US 5626865 which is a continuation-in-part of Ser. No. US 1991-776211, filed on 15 Oct 1991, now patented, Pat. No. US 5270051		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Krass, Frederick		
LEGAL REPRESENTATIVE:	Knobbe, Martens, Olson & Bear, LLP		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	1703		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and apparatus for correcting refractive errors of the eye are disclosed. Accelerated reshaping of the **corneal** tissue is accomplished by administering one or more enzymes and/or other agents to the eye which temporarily soften the **cornea**. The **cornea** is thereafter fitted with a rigid **contact lens** or a series of lenses which have a concave curvature that will correct a refractive error. The softened **cornea** then rapidly reshapes its convex curvature to the concave curvature of the **contact lens** or series of lenses, thereby rendering the eye emmetropic. The enzymes and/or other agents then dissipate from the **cornea**, and the **cornea** "hardens" to retain the new emmetropic shape. After "hardening" has occurred, the lens rendering the eye emmetropic is removed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 15 OF 18 USPATFULL
ACCESSION NUMBER: 97:38211 USPATFULL
TITLE: Enzyme-orthokeratology
INVENTOR(S): Harris, Donald H., Laguna Niguel, CA, United States
May, Charles, San Diego, CA, United States
Karageozian, Hampar, San Juan Capistrano, CA, United States
PATENT ASSIGNEE(S): Advanced Corneal Systems, Inc., Irvine, CA, United States (U.S. corporation

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5626865		19970506	
	WO 9307840		19930429	
APPLICATION INFO.:	US 1994-211749		19940718	(8)
	WO 1992-US8791		19921015	
			19940718	PCT 371 date
			19940718	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-776211, filed on 15 Oct 1991, now patented, Pat. No. US 5270051
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Krass, Frederick
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and apparatus for correcting refractive errors of the eye are disclosed. Accelerated reshaping of the **corneal** tissue is accomplished by administering one or more enzymes and/or other agents to the eye which temporarily soften the **cornea**. The **cornea** is thereafter fitted with a rigid **contact lens** or a series of lenses which have a concave curvature that will correct a refractive error. The softened **cornea** then rapidly reshapes its convex curvature to the concave curvature of the **contact lens** or series of lenses, thereby rendering the eye emmetropic. The enzymes and/or other agents then dissipate from the **cornea**, and the **cornea** "hardens" to retain the new emmetropic shape. After "hardening" has occurred, the lens rendering the eye emmetropic is removed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 16 OF 18 USPATFULL
ACCESSION NUMBER: 93:76417 USPATFULL
TITLE: Preparation of a polymeric hydrogel containing micropores and macropores for use as a cell culture substrate
INVENTOR(S): Anderson, David M., 337 Squire Hall Suny, Buffalo, NY, United States 14214

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5244799		19930914	
APPLICATION INFO.:	US 1991-809259		19911217	(7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1990-574506, filed on 23 Aug 1990, now abandoned which is a continuation of Ser. No. US 1989-323616, filed on 14 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-292015, filed on 30 Dec 1988, now abandoned which

is a continuation-in-part of Ser. No. US 1987-52713, filed on 20 May 1987, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Naff, David M.
LEGAL REPRESENTATIVE: Blodgett & Blodgett
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 595
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A hydrophilic substituent of a bicontinuous cubic phase in equilibrium is polymerized and the unpolyermized components subsequently removed and replaced with water, creating a hydrogel which is locally highly cross-linked but of high water content because of the presence of a periodic network of water-filled macropores superposed on the hydrogel matrix. The diameter of these "macropores" can be preselected between 20 Angstroms and several hundred Angstroms or even higher, and in general will be much larger than the "micropores" within the hydrogel portions of the final material. The material has high water content, good mechanical integrity and notch strength, high permeability to oxygen, and the pore size can be chosen to allow passage of molecules of pre-selected size. The material is useful as a cell culture substrate and in a **contact lens** and other biological and medical applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 17 OF 18 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1159941 EUROPATFULL EW 200149 FS OS
TITLE: Formulations for use in enzyme-orthokeratology.
Zusammensetzung zur Verwendung in der Enzymkeratologie.
Formulations pour usage dans l'orthokeratologie enzymatique.
INVENTOR(S): Harris, Donald H., 1303 Avocado, Suite 100, Newport Beach, CA 92680, US;
May, Charles, 3311 Fourth Avenue, San Diego, CA 92103, US;
Karageozian, Hampar, 31021 Marbella Vista, San Juan Capistrano, CA 92675, US
PATENT ASSIGNEE(S): Ista Pharmaceuticals, Inc., 1414 Muirlands Drive, La Jolla, CA 92307, US
PATENT ASSIGNEE NO: 1643982
AGENT: Hepworth, John Malcolm et al., Hepworth Lawrence Bryer & Bizley Merlin House, Falconry Court, Baker's Lane, Epping, Essex CM16 5DQ, GB
AGENT NUMBER: 31746
OTHER SOURCE: BEPA2001098 EP 1159941 A2 0031
SOURCE: Wila-EPZ-2001-H49-T2b
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R NL; R SE
PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1159941	A2	20011205
'OFFENLEGUNGS' DATE:		20011205
APPLICATION INFO.: EP 2001-203285		19921015

PRIORITY APPLN. INFO.: US 1991-776211 19911015
RELATED DOC. INFO.: EP 608341 DIV

L12 ANSWER 18 OF 18 EUROPATFULL COPYRIGHT 2003 WILA

GRANTED PATENT ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 608341 EUROPATFULL EW 200213 FS PS
TITLE: ENZYME-ORTHOKERATOLOGY.
ENZYMORTHOKERATOLOGIE.
ORTHOKERATOLOGIE ENZYMATIQUE.
INVENTOR(S): HARRIS, Donald, H., 200 Newport Center Drive, Suite 110, Newport Beach, CA 92660, US;
MAY, Charles, 3811 Fourth Avenue, San Diego, CA 92103, US;
KARAGEOZIAN, Hampar, 31021 Marbella Vista, San Juan Capistrano, CA 92675, US
PATENT ASSIGNEE(S): Ista Pharmaceuticals, Inc., 1414 Muirlands Drive, La Jolla, CA 92307, US
PATENT ASSIGNEE NO: 1643982
AGENT: Williams, Richard Andrew Norman et al., Hepworth Lawrence Bryer & Bizley Merlin House Falconry Court Bakers Lane, Epping, Essex CM16 5DQ, GB
AGENT NUMBER: 77491
OTHER SOURCE: BEPB2002023 EP 0608341 B1 0028
SOURCE: Wila-EPS-2002-H13-T2
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R NL; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 608341	B1	20020327
'OFFENLEGUNGS' DATE:		19940803
APPLICATION INFO.:	EP 1992-922291	19921015
PRIORITY APPLN. INFO.:	US 1991-776211	19911015
RELATED DOC. INFO.:	WO 92-US8791	921015 INTAKZ
	WO 9307840	930429 INTPNR
REFERENCE PAT. INFO.:	DE 2308144 A	DE 2426757 A
	DE 861753 C	US 1929228 A
	US 3416530 A	US 3485244 A
	US 3760807 A	US 4540417 A